June 24, 2021

June 24, 2021 – Elevation Oncology, Inc. (NASDAQ: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at a public offering price of $16.00 per share. All of the shares were offered by Elevation Oncology. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Elevation Oncology, were $115 million. The shares began trading on the Nasdaq Global Select Market on June 25, 2021 under the ticker symbol “ELEV.” FLG partner Eric Hall assisted.

Full press release is here.